Pembrolizumab

Research study shows merits of using Pembrolizumab as first line treatment of patients with advanced non-small-cell lung cancer and high PD-L1 expression

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression, according to the results of the phase III KEYNOTE-024 trial presented at the ESMO 2016 Congress in Copenhagen1 and published in the New England Journal of Medicine. ”Pembrolizumab is a PD-1 antibody approved …

Research study shows merits of using Pembrolizumab as first line treatment of patients with advanced non-small-cell lung cancer and high PD-L1 expression Read More »

Chemotherapy and pembrolizumab combination significantly improves outcomes in advanced non-small-cell lung cancer

The addition of PD-1 antibody pembrolizumab to standard first-line chemotherapy for treatment-naïve advanced non-small-cell lung cancer significantly improves response rates and progression-free survival, researchers reported at the ESMO 2016 Congress in Copenhagen today. Pembrolizumab is a class of immunotherapeutic anti-cancer drugs called checkpoint inhibitors, which target the mechanism the tumor uses to shut down the …

Chemotherapy and pembrolizumab combination significantly improves outcomes in advanced non-small-cell lung cancer Read More »